AMRX vs SPRY
AMRX: Amneal Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of a diverse portfolio of generic and specialty medicines. SPRY: ARS Pharmaceuticals has developed neffy, the first FDA-approved needle-free intranasal epinephrine spray for the emergency treatment of severe allergic reactions.
Side-by-side fundamentals
| Metric | AMRX | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $20.20 | $4.18 | |
| Market cap | $6.5B | $416M | |
| P/E as of 2026-10-21 | 42.08 | n/a | |
| Net margin FY2025, SEC XBRL | +2.4% | -203.3% | AMRX higher |
| Gross margin FY2025, SEC XBRL | +36.9% | n/a | |
| Operating margin FY2025, SEC XBRL | +13.1% | -212.9% | AMRX higher |
| ROE FY2025, SEC XBRL | n/a | -149.9% | |
| ROA FY2025, SEC XBRL | +2.0% | -52.3% | AMRX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 77.83 | 7.73 | SPRY lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.1% | -5.5% | AMRX higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +300.1% | SPRY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.82 | 1.01 | |
| 1-year return as of 2026-10-21 close | +96.3% | -57.8% | AMRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.